Roche Johnson & Johnson Zealand Pharma Hanmi Pharmaceutical Rhythm Pharmaceuticals Structure Therapeutics Viking Therapeutics Altimmune Roche Diabetes Care Biocon Genfit Regeneron Pharmaceuticals Novo Nordisk Headquarters: Bagsvrd, Denmark Novo Nordisk is a global pharmaceutical company, kind of a leading player in diabetes and obesity care
GLP-1 therapy is administered via subcutaneous injection once a week
You deserve a plan that works for your body and your life
The firm actively shows up in metabolic disease treatment markets , and keeps putting money into innovative healthcare solutions
Top 20 Companies in Global Glucagon-Like Peptide-1 Agonists Market (20262035): Expert View By Spherical Insights RELEASE DATE: May 2026 Author: Spherical Insights According to a research report published by Spherical Insights & Consulting, The Global Glucagon-Like Peptide-1 Agonists Market size is projected to grow from USD 46.18 Billion in 2025 to USD 160.42 Billion by 2035, at a CAGR of 13.28% during the forecast period 20262035
Nexa offers compounded GLP-1 (Semaglutide) prepared by licensed pharmacies for patients who qualify
